Efficacy of 177-Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues

被引：0
|
作者：
Ratnayake, G. M. [1 ]
Koffas, A. [1 ]
Theocharopoulos, I [1 ]
Hayes, A. [1 ]
Navalkissoor, S. [1 ]
Gnanasegaran, G. [1 ]
Quigley, A. M. [1 ]
Khoo, B. [1 ]
Mandair, D. [1 ]
Grossman, A. [1 ]
Caplin, M. [1 ]
Alsadik, S. [1 ]
Clark, R. [1 ]
Toumpanakis, C. [1 ]
机构：
[1] Royal Free Hosp, ENETS Ctr Excellence, London, England
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
carcinoid syndrome; prrt;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H24
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [21] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Zhang, Jie
    Song, Qi
    Cai, Liang
    Xie, Ying
    Chen, Yue
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1533 - 1543
  • [22] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Jie Zhang
    Qi Song
    Liang Cai
    Ying Xie
    Yue Chen
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1533 - 1543
  • [23] Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
    Pretot, Dominique
    Engel-Bicik, Ivette
    Kenkel, David
    Kaufmann, Philipp A.
    Treyer, Valerie
    Siebenhuner, Alexander R.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (03) : 1204 - 1217
  • [24] A Prospective study of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE and Concurrent Capecitabine in Metastatic Paragangliomas
    Ballal, S.
    Yadav, M. P.
    Yadav, D.
    Bal, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S184 - S184
  • [25] Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE
    Zandee, Wouter T.
    Feelders, Richard A.
    Duijzentkunstz, Daan A. Smit
    Hofland, Johannes
    Metselaar, R. Mick
    Oldenburg, Rogier A.
    van Linge, Anne
    Kam, Boen L. R.
    Teunissen, Jaap J. M.
    Korpershoek, Esther
    Hendriks, Johanna M.
    Abusaris, Huda
    Slagter, Cleo
    Franssen, Gaston J. H.
    Brabander, Tessa
    De Herder, Wouter W.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2019, 181 (01) : 45 - 53
  • [26] Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90-Yttrium versus 177-Lutetium - Comparison of clinico-pathological and survival outcomes
    Genova, L.
    Andreasi, V
    Partelli, S.
    Muffatti, F.
    Battistella, A.
    Crippa, S.
    Tamburrino, D.
    Pecorelli, N.
    Balzano, G.
    Falconi, M.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 187 - 187
  • [27] Efficacy of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Inoperable/Metastatic, Progressing Neuroendocrine Tumors: Results of Our First Clinical Experience
    Gunalp, B.
    Ucgun, A.
    Goker, U.
    Mahmudov, S.
    Ince, S.
    Alagoz, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S641 - S642
  • [28] A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
    Becx, Morticia N.
    Minczeles, Noemie S.
    Brabander, Tessa
    de Herder, Wouter W.
    Nonnekens, Julie
    Hofland, Johannes
    CANCERS, 2022, 14 (23)
  • [29] Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting
    Kalshetty, Ashwini
    Ramaswamy, Anant
    Ostwal, Vikas
    Basu, Sandip
    NUCLEAR MEDICINE COMMUNICATIONS, 2018, 39 (12) : 1143 - 1149
  • [30] Validation of an in-house developed therapeutic dosimetric software tool for the treatment of 177Lutetium-DOTATATE peptide receptor radionuclide therapy
    Bronwin Van Wyk
    Francis Hasford
    Nozipho Nyakale
    Mboyo-Di-Tamba Vangu
    Health and Technology, 2024, 14 : 277 - 289
12345